About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era

Citation:

European Cardiology Review 2017;12(2):89–91

Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy

Citation:

European Cardiology Review 2017;12(2):88

Optical Coherence Tomography For the Detection of the Vulnerable Plaque

Citation:

European Cardiology Review 2016;11(2):90–5

Antiplatelet Therapy in Acute Coronary Syndrome

Citation:

European Cardiology Review 2017;12(1):33–7.